| |
Sept. 25 - 26, 2024 | San Diego, CA Learn out of the box strategies for MSLs to engage with KOLs and HCPs post-pandemic, successful approaches to establishing medical communications plans ahead of a launch. Complimentry Passes Available! Learn More. .png)
|
|
Today’s Big NewsAug 5, 2024 |
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria. 
|
|
| By James Waldron BioNTech may still claim that the bispecific antibody acasunlimab has an “encouraging” clinical profile, but the mRNA leader has opted to end its involvement and allow partner Genmab to go solo for phase 3 trials. |
|
|
|
By Annalee Armstrong Zevra Therapeutics’ rare disease drug seems to be on the path to approval this fall after gaining the backing of an FDA advisory committee, although the experts were split, with some voting yes simply to address an unmet need. |
By Annalee Armstrong This year's Fierce 15 features companies pushing the envelope in the lab, clinic and boardroom. |
By Nick Paul Taylor Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. |
|
Maximize Your Brand Exposure From brand awareness to lead generation, our tailored marketing solutions help you achieve your objectives. Get noticed, start conversations, and drive demand with Fierce Biotech. Learn more now. 
|
|
By Nick Paul Taylor The FDA has torpedoed Actinium Pharmaceuticals’ hopes of winning a blood cancer approval based on existing data. With the agency requesting an additional head-to-head randomized clinical trial, Actinium is planning to try to partner the program and switch its attention to other candidates. |
By James Waldron After taking a look at phase 1 data, Nuvation Bio has decided to halt work on its one-time lead BD2-selective BET inhibitor while considering the program’s future. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Darren Incorvaia Flesh-eating bacteria sound like something an enterprising science fiction author would dream up, but they are in fact real—and the infections they cause can lead to disfigurement, loss of limbs, and even death. |
By Angus Liu On June 14, Merck & Co. posted a new entry on ClinicalTrials.gov. The study marked the 10th global phase 3 trial that the New Jersey pharma has logged for its Kelun Biotech-partnered ADC, sacituzumab tirumotecan, in about eight months. And Merck isn’t finished. |
By Fraiser Kansteiner While Pfizer’s German mRNA partner BioNTech has high hopes for its post-COVID future, the company continues to feel the squeeze from the changeover to a seasonal vaccine market. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany. |
|
|---|
|
|
|
Thursday, September 5, 2024 | 12pm ET / 9am PT Liquid biopsy is emerging as a revolutionary technology, offering swift and precise diagnostics. However, it still faces key challenges. Join us to learn more about the collaborative efforts of SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca that are aimed at addressing disparities in cancer care. Register now. 
|
|
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
